For the quarter ending 2026-03-31, RGEN has $2,930,772K in assets. $825,309K in debts. $582,650K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 582,650 | 566,021 | 748,747 | 708,855 |
| Marketable securities | 201,881 | 201,607 | - | - |
| Accounts receivable, net of allowances of 2,709 and 2,767 at march 31, 2026 and december 31, 2025, respectively | 151,552 | 158,587 | 148,970 | 156,952 |
| Total noncurrent assets | - | 1,812,314 | 1,827,226 | 1,844,762 |
| Inventories, net | 179,256 | 170,458 | 160,320 | 155,862 |
| Prepaid expenses and other current assets | 46,021 | 40,712 | 38,448 | 35,196 |
| Total current assets | 1,161,360 | 1,137,385 | 1,096,485 | 1,056,865 |
| Property, plant and equipment, net | 173,461 | 186,614 | 188,927 | 193,489 |
| Gross carrying value | 581,720 | 594,218 | - | - |
| Indefinite-lived intangible asset | 700 | 700 | - | - |
| Gross carrying value | 582,420 | 594,918 | - | - |
| Accumulated amortization | 214,232 | 208,771 | - | - |
| Intangible assets, net | 368,188 | 386,147 | 395,442 | 406,213 |
| Goodwill | 1,106,874 | 1,114,408 | 1,112,735 | 1,114,009 |
| Deferred tax assets | 1,362 | 694 | 856 | 800 |
| Operating lease right of use assets | 113,644 | 119,538 | 124,161 | 127,682 |
| Other noncurrent assets | 5,883 | 4,913 | 5,105 | 2,569 |
| Total assets | 2,930,772 | 2,949,699 | 2,923,711 | 2,901,627 |
| Accounts payable | 34,657 | 30,010 | 29,426 | 25,625 |
| Operating lease liabilities | 21,071 | 21,559 | 19,314 | 16,043 |
| Contingent consideration | 5,226 | 5,049 | 5,107 | 5,168 |
| Accrued liabilities | 65,255 | 79,208 | 77,289 | 76,176 |
| Total current liabilities | 126,209 | 135,826 | 131,136 | 123,012 |
| Convertible senior notes due 2028, net | 546,585 | 542,213 | 537,927 | - |
| Deferred tax liabilities | 15,018 | 22,496 | 20,135 | 23,326 |
| Convertible senior notes due 2028, net | - | - | - | 533,725 |
| Noncurrent operating lease liabilities | 119,964 | 126,176 | 131,626 | 136,296 |
| Noncurrent contingent consideration | 778 | 1,304 | 2,478 | 6,658 |
| Other noncurrent liabilities | 16,755 | 15,555 | 17,322 | 16,869 |
| Total noncurrent liabilities | - | 707,744 | 709,488 | 716,874 |
| Total liabilities | 825,309 | 843,570 | 840,624 | 839,886 |
| Common stock, 0.01 par value 80,000,000 shares authorized 56,399,294 shares at march 31, 2026 and 56,325,429 shares at december 31, 2025 issued and outstanding | 564 | 563 | 563 | 563 |
| Additional paid-in capital | 1,654,627 | 1,651,849 | 1,643,670 | 1,634,844 |
| Accumulated other comprehensive loss | -14,309 | -2,531 | -4,107 | -1,716 |
| Retained earnings | 464,581 | 456,248 | 442,961 | 428,050 |
| Total stockholders' equity | 2,105,463 | 2,106,129 | 2,083,087 | 2,061,741 |
| Total liabilities and stockholders' equity | 2,930,772 | 2,949,699 | 2,923,711 | 2,901,627 |
REPLIGEN CORP (RGEN)
REPLIGEN CORP (RGEN)